Index 385language disorders, 244–9
associated problems, 248–9
differential diagnosis and assessment, 49–50,
142, 143, 247
varieties, 245–6
language problems, 142
Lesch–Nyhan syndrome, 9, 236
linear causality, 344, 345
lithium, 76, 107, 113, 169, 324
looked-after children and adolescents, 361–9
assessment considerations, 364
identity and contact issues, 365–6
interventions, 367–8
placement decision issues, 364–5
psychopathology, 35 , 363–4
work with foster or adoptive parents, 366–7
maltreatment, 210–25
assessment, 16, 221–3
clinical view, 212–16
effects, 73, 217–21
epidemiology, 211
intervention, 223–4
risk factors, 216, 217
see alsoemotional abuse; neglect; physical
abuse; sexual abuse
mania, 109, 110, 111, 195
see alsobipolar disorder
medication
drug groups, 321–5
antiepileptic medications, 53, 113, 241,
242, 324–5
benzodiazepines and minor tranquillizers,
168, 169, 170, 325
clonidine (alpha-2 agonist), 62, 139, 322
lithium, 76, 107, 113, 169, 324
monoamine oxidase inhibitors, 323
neuroleptics, 54, 76, 107, 113, 138–9,
196 , 197, 237–8, 323–4
selective serotonin reuptake inhibitors,
54, 93, 100, 106, 121, 134, 144, 202,
305, 323
stimulants, 54, 62, 76, 163, 169, 238,
321–2
tricyclic antidepressants, 62–3, 93, 156,
169, 305, 322–3
general principles, 319–21
see also specific drugs
melatonin, 163, 170
methylphenidate, 62, 169, 321
Milan systemic family therapy, 347, 354–8
example, 356
techniques, 355–8
misery, 102, 105, 191
monoamine oxidase inhibitors (MAOIs), 323
mood stabilisers, 76, 107, 113, 169, 324–5
Multidimensional Treatment Foster Care
(MTFC) approach, 87, 367–8
multi-domain symptoms, 6–8
Multisystemic Therapy (MST), 86–7, 359
Munchausen syndrome by proxy, 212–13
mutism, selective, 141–4
narcolepsy, 164, 168–9
narrative approach to therapy, 347, 358
narrative exposure therapy, 127–8
nature v. nurture debate, 270–81
disruptive behavioural disorders, 72
negative reinforcement, 328, 331
neglect, 210, 213–14
neonatal screening, 233
neurocutaneous disorders, 20
neurodegenerative disorders, 50
neurofibromatosis-1, 20
Neuroleptic Malignant Syndrome, 324
neuroleptics, 54, 76, 107, 113, 138–9, 196 , 197,
237–8, 323–4
neurological examination, 18–20
night terrors, 163, 168
nightmares, 163, 168
nocturnal enuresis, 151, 152–6
non-organic failure to thrive (NOFT), 213
non-shared environment, 272–3
effects, 273 , 274
observation studies/techniques, 6, 15, 32, 75
obsessive-compulsive disorder (OCD)
associated features, 132, 137
causation, 133–4
characteristic features, 131–2
differential diagnosis, 132–3
onset and prevalence, 4, 131
prognosis, 134–5
treatment, 134
obstructive sleep apnoea, 164, 167
Office for National Statistics surveys, 33 , 71,
363
operant conditioning, 96, 328
oppositional-defiant disorder, 27 , 65, 68 , 184
over-correction, 332
PANDAS syndrome, 134, 138
panic attacks, 100, 125, 163
paradox/counterparadox, 358
paradoxical communication, 351
parasuicide, 118
parent-management training, 61–2, 75, 87
parental mental health problems, 286
parental reports, 4–5
parenting [educational] programmes, 87,
315–16, 316–17
parents
disruptive behaviour affected by, 73, 74–5
history taking from, 13–15
peer relationships, 294–6
persistence, 34 ,38
personality disorders, 84
pervasive developmental disorders, 26, 45
pervasive symptoms, 5, 25–6, 59
pharmacodynamics, 321
pharmacokinetics, 319–20
phobias, 92, 97–8
physical abuse, 210, 212–13
physical examination, 10, 18–20
for suspected abuse, 222–3